Document:

Exhibit
10.2

 

Fifth
AMENDMENT TO EMPLOYMENT AGREEMENT

 

This
fifth AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”),
is entered into as of August 30, 2022 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”)
and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement,
dated as of November 1, 2020, and as amended on December 18, 2020, January 8, 2021, February 10, 2021, and November 24, 2021, by and
between Employee and the Company (the “Agreement”). Terms used in this Amendment with initial capital letters
that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

 

WHEREAS,
Section 16 of the Agreement provides that no waiver or modification of any provision of the Agreement will be enforceable unless it is
agreed to in writing by the party against which enforcement would be sought; and

 

WHEREAS,
the Parties mutually desire to modify certain provisions that would otherwise apply to Bonus Compensation potentially payable to Employee
pursuant to the Agreement.

 

NOW,
THEREFORE, pursuant to Section 16 of the Agreement, in consideration of the mutual provisions, conditions, and covenants contained
herein, and other good and valuable consideration, the adequacy of which is hereby acknowledged, the Parties hereby agree as follows:

 

In
Exhibit B to the Agreement, Bonus Compensation, paragraph 5 is hereby deleted and replaced with the following:

 

“5)
Bonus Compensation of $100,000 cash to be paid in lump-sum cash upon the completion of the following Bonus Event: the establishment of
a formal relationship with the Bascom Palmer Eye Institute to advance, participation in and/or support of the use of MYMD-1 in ocular
disease preclinical or clinical applications provided that the nature and/or extent of the Bascom Palmer Eye Institute relationship is
satisfactory in the discretion of the Company’s Board of Directors.”

 

[Remainder
of the Page Intentionally Left Blank;

Signature
Page Follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the Effective Date.

 

	 	EMPLOYEE:
    
	 	 	 
	 	/s/ Chris Chapman, M.D.
	 	Chris Chapman, M.D.
	 	 	 
	 	THE
    COMPANY: 
	 	 	 
	 	By:	/s/
    Paul M. Rivard
	 	Name:	Paul
    M. Rivard
	 	Title:	Executive
    Vice PresidentExhibit
10.3

 

Third
AMENDMENT TO EMPLOYMENT AGREEMENT

 

This
third AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”),
is entered into as of August 30, 2022 (the “Effective Date”), by and between Adam Kaplin, M.D. (“Employee”)
and MyMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement,
dated as of December 18, 2020, and as amended on February 10, 2021 and November 24, 2021, by and between Employee and the Company (the
“Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein
shall have the meanings ascribed to such terms in the Agreement.

 

WHEREAS,
Section 17 of the Agreement provides that no waiver or modification of any provision of the Agreement will be enforceable unless it is
agreed to in writing by the party against which enforcement would be sought; and

 

WHEREAS,
the Parties mutually desire to modify certain provisions that would otherwise apply to Bonus Compensation potentially payable to Employee
pursuant to the Agreement.

 

NOW,
THEREFORE, pursuant to Section 17 of the Agreement, in consideration of the mutual provisions, conditions, and covenants contained
herein, and other good and valuable consideration, the adequacy of which is hereby acknowledged, the Parties hereby agree as follows:

 

In
Exhibit B to the Agreement, Bonus Compensation, paragraph 5 is hereby deleted and replaced with the following:

 

“5)
Bonus Compensation of $100,000 cash to be paid in lump-sum cash upon the completion of the following Bonus Event: the establishment of
a formal relationship with the Bascom Palmer Eye Institute to advance, participation in and/or support of the use of MYMD-1 in ocular
disease preclinical or clinical applications provided that the nature and/or extent of the Bascom Palmer Eye Institute relationship is
satisfactory in the discretion of the Company’s Board of Directors.”

 

[Remainder
of the Page Intentionally Left Blank;

Signature
Page Follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement to be effective as of the Effective Date.

 

	 	EMPLOYEE:
    
	 	 	 
	 	/s/ Adam Kaplin, M.D.
	 	Adam Kaplin, M.D.
	 	 	 
	 	THE
    COMPANY: 
	 	 	 
	 	By:	/s/
    Chris Chapman, M.D.
	 	Name:	Chris
    Chapman, M.D.
	 	Title:	PresidentExhibit
10.6

 

Pono
Capital Corp

643
Ilalo Street

Honolulu,
Hawaii 96813

 

November
9, 2022

 

Ladies
and Gentlemen:

 

Pono
Capital Corp (the “Company”), a blank check company formed for the purpose of acquiring one or more businesses or entities
(a “Business Combination”), may extend the date on which it must wind-up and liquidate pursuant to its organizational documents,
for up to two 3-month periods to the date that is 18 months after the closing of the Company’s initial public offering, by depositing
$1,150,000 per extension (each, an “Extension Fee”) into the Company’s trust account with Continental Stock Transfer
& Trust Company (the “Trustee”).

 

Mehana
Capital LLC (“Mehana Capital”) has agreed to purchase securities from the Company for a purchase price that will enable payment
of half of the Extension Fees necessary to extend the date of the Company’s wind-up and liquidation to February 13, 2023, the date
that is 18 months after the closing of the Company’s initial public offering. Concurrently, AERWINS Technologies, Inc. will purchase
securities from the Company that will enable payment of the remaining half of the Extension Fees for the second extension. Accordingly,
Mehana Capital hereby commits that it will purchase 57,500 units of the Company (“Private Units”), each Private Unit consisting
of one share of Class A common stock of the Company, par value $0.000001 per share (the “Class A Common Stock”), and three-quarters
of one warrant (the “Warrants”), with each whole warrant entitling its holder to purchase one (1) share of Class A Common
Stock, for an aggregate purchase price of $575,000 (the “Private Unit Purchase Price”), to be paid directly to the Trustee
to fund the second Extension Fee.

 

On
or before November 9, 2022, Mehana Capital will cause the Private Unit Purchase Price to be delivered to the Trustee, by wire transfer
as set forth in the instructions attached as Exhibit A to be held in the Trust Account.

 

Each
of the Company, and the undersigned acknowledges and agrees that the Trustee is serving hereunder solely as a convenience to the parties
to facilitate the purchase of the Private Units and the Trustee’s sole obligation under this letter agreement is to act with respect
to holding and disbursing the Private Unit Purchase Price as described above. The Trustee shall not be liable to the Company, or the
undersigned or any other person or entity in respect of any act or failure to act hereunder or otherwise in connection with performing
its services hereunder unless the Trustee has acted in a manner constituting gross negligence or willful misconduct. The Company and
the undersigned shall indemnify the Trustee against any claim made against it (including reasonable attorney’s fees) by reason
of it acting or failing to act in connection with this letter agreement except as a result of its gross negligence or willful misconduct.
The Trustee may rely and shall be protected in acting or refraining from acting upon any written notice, instruction or request furnished
to it hereunder and believed by it to be genuine and to have been signed or presented by the proper party or parties.

 

The
Private Units will be identical to the units sold by the Company in the IPO. Additionally, the undersigned agrees:

 

	 	●	to
    vote the shares of Class A Common Stock included in the Private Units in favor of any proposed Business Combination;
	 	 	 
	 	●	not
    to propose, or vote in favor of, an amendment to the Company’s Amended and Restated Certificate of Incorporation that would
    affect the substance or timing of the Company’s obligation to redeem 100% of the Company’s shares of Class A Common Stock
    sold in the IPO if the Company does not complete an initial Business Combination within 12 months from the closing of the IPO (or
    up to 18 months from the closing of the IPO if the Company extends the period of time to consummate an initial Business Combination
    as described in more detail in the prospectus included in the Registration Statement), unless the Company provides the holders of
    shares of Class A Common Stock sold in the IPO with the opportunity to redeem their shares of Class A Common Stock upon approval
    of any such amendment at a per-share price, payable in cash, equal to the aggregate amount of the Trust Account, including interest
    earned on Trust Account and not previously released to the Company to pay the Company’s franchise and income taxes, divided
    by the number of then outstanding shares of Class A Common Stock sold in the IPO;

 

    	 

     

    

 

	 	●	not
    to convert any shares of Class A Common Stock included in the Private Units into the right to receive cash from the Trust Account
    in connection with a shareholder vote to approve either a Business Combination or an amendment to the provisions of the Company’s
    Amended and Restated Certificate of Incorporation, and not to tender the Private Units in connection with a tender offer conducted
    prior to the closing of a Business Combination;
	 	 	 
	 	●	the
    undersigned will not participate in any liquidation distribution with respect to the Private Units (but will participate in liquidation
    distributions with respect to any units or shares of Class A Common Stock purchased by the undersigned in the IPO or in the open
    market) if the Company fails to consummate a Business Combination; and
	 	 	 
	 	●	that
    the Private Units, and underlying securities will not be transferable until after the consummation of a Business Combination except
    (i) to the Company’s pre-IPO shareholders, or to the Company’s officers, directors, advisors and employees, (ii) transfers
    to the undersigned’s affiliates or its members upon its liquidation, (iii) to relatives and trusts for estate planning purposes,
    (iv) by virtue of the laws of descent and distribution upon death, (v) pursuant to a qualified domestic relations order, (vi) by
    private sales made in connection with the consummation of a Business Combination at prices no greater than the price at which the
    Private Units were originally purchased or (vii) to the Company for cancellation in connection with the consummation of a Business
    Combination, in each case (except for clause vii) where the transferee agrees to the terms of the transfer restrictions.

 

The
undersigned hereby represents and warrants that:

 

	 	(a)	it
    has been advised that the Private Units have not been registered under the Securities Act;
	 	 	 
	 	(b)	it
    will be acquiring the Private Units for its account for investment purposes only;
	 	 	 
	 	(c)	it
    has no present intention of selling or otherwise disposing of the Private Units in violation of the securities laws of the United
    States;
	 	 	 
	 	(d)	it
    is an “accredited investor” as defined by Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended;
	 	 	 
	 	(e)	it
    has had both the opportunity to ask questions and receive answers from the officers and directors of the Company and all persons
    acting on its behalf concerning the terms and conditions of the offer made hereunder;
	 	 	 
	 	(f)	it
    is familiar with the proposed business, management, financial condition and affairs of the Company;
	 	 	 
	 	(g)	it
    has full power, authority and legal capacity to execute and deliver this letter and any documents contemplated herein or needed to
    consummate the transactions contemplated in this letter; and
	 	 	 
	 	(h)	this
    letter constitutes its legal, valid and binding obligation, and is enforceable against it.

 

This
letter agreement constitutes the entire agreement between the undersigned and the Company with respect to the purchase of the Private
Units, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral,
with respect to the same.

 

	 	Very
    truly yours,
	 	 	 
	 	MEHANA
    CAPITAL LLC 
	 	 	 
	 	By:	/s/
    Dustin Shindo 
	 	Name:	 Dustin
    Shindo
	 	Title:	Manager

 

	Accepted
    and Agreed:  	 
	   	 
	PONO
    CAPITAL CORP  	 
	 	 	 
	By:	 /s/
    Dustin Shindo	 
	Name:	Dustin
    Shindo	 
	Title:	Chief
    Executive Officer	 

 

    	 

     

    

 

Exhibit
A

 

Trustee

 

Wire
Instructions

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]